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Abstract
A high load of white matter lesions and enlarged basilar arteries have been shown in selected patients with Fabry disease, a
disorder associated with an increased stroke risk. We studied a large cohort of patients with Fabry disease to differentially
investigate white matter lesion load and cerebral artery diameters. We retrospectively analyzed cranial magnetic resonance
imaging scans of 87 consecutive Fabry patients, 20 patients with ischemic stroke, and 36 controls. We determined the white
matter lesion load applying the Fazekas score on fluid-attenuated inversion recovery sequences and measured the
diameters of cerebral arteries on 3D-reconstructions of the time-of-flight-MR-angiography scans. Data of different Fabry
patient subgroups (males – females; normal – impaired renal function) were compared with data of patients with stroke and
controls. A history of stroke or transient ischemic attacks was present in 4/30 males (13%) and 5/57 (9%) females with Fabry
disease, all in the anterior circulation. Only one man with Fabry disease showed confluent cerebral white matter lesions in
the Fazekas score assessment (1%). Male Fabry patients had a larger basilar artery (p,0.01) and posterior cerebral artery
diameter (p,0.05) compared to male controls. This was independent of disease severity as measured by renal function and
did not lead to changes in arterial blood flow properties. A basilar artery diameter of .3.2 mm distinguished between men
with Fabry disease and controls (sensitivity: 87%, specificity: 86%, p,0.001), but not from stroke patients. Enlarged arterial
diameters of the posterior circulation are present only in men with Fabry disease independent of disease severity.
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Introduction
Fabry disease (FD) is an X-linked recessive lysosomal storage
disorder with deficient activity of the enzyme a-galactosidase A (a-
GAL). Enzyme deficiency is caused by mutations in the GLA-gene
and leads to an accumulation of the glycosphingolipid globotriao-
sylceramide (Gb3) in kidneys, heart, and the nervous system [1].
The brain is mainly affected by a small vessel vasculopathy [2,3]
and white matter lesions (WML). FD is also a cause of stroke at
young age [4–8].
Cerebral blood vessels of FD patients have been studied with
Doppler sonography [9–11] and magnetic resonance imaging
(MRI). In two studies of the same group of 25 FD patients cerebral
artery diameters were measured using MRI with time-of-flight
(TOF) MR-angiography (MRA) [12,13]. The authors found an
increased diameter of the basilar artery in FD patients compared
to healthy controls and to stroke patients and suggested that the
basilar artery diameter might be a diagnostic tool to detect FD
patients among young patients with ischemic stroke [13]. Here we
asked, whether these findings were true also in a large cohort of
FD patients seen at our center, whether they were valid for
women, and whether basilar artery diameter was dependent on
disease severity as measured by renal function. We also assessed
WML load and compared our results with non-FD patients with
ischemic stroke and with controls.
Patients and Methods
Standard protocol approvals and patient consents
The study was approved by the Wu¨rzburg Medical School
Ethics Committee. Written informed consent was obtained from
all study participants at the time of examination.
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Subjects
In this retrospective study we analyzed data of 87 FD patients
from the Wu¨rzburg University Hospital. These patients consec-
utively reported at the Wu¨rzburg Fabry Center for Interdisciplin-
ary Therapy (FAZIT), and were examined at the Department of
Neurology. FAZIT is a tertiary referral center where patients are
seen from all over Germany mainly to confirm the diagnosis and
to decide on the treatment. The MRI scans were performed at the
Department of Neuroradiology as part of the routine work-up of
Fabry patients. The patient group consisted of 30 men (median
age 40 years, range 16–40 years) and 57 women (median age 45
years, range 16–73 years). Patients were included if FD was
confirmed by a-GAL assay and genetically ascertained. Data on
the peripheral nervous system [14] and on cerebral blood flow as
measured by Doppler sonography [11] of some of these patients
have been described elsewhere. More women with FD were
included due to the higher number of men who carried cardiac
defibrillators as contraindications for MRI scans.
We additionally analyzed data of 20 patients with cerebral
ischemic stroke who were seen at our Department of Neurology
between 2007 and 2012. This patient group consisted of 13 men
(median age 58 years, range 49–89 years) and 7 women (median
age 75 years, range 49–94years). Patients were included only, if
cerebral ischemic stroke was confirmed by diffusion-weighted
MRI, and if MRA had been performed.
Patients` data were compared with data of a group of 36 subjects
with normal MRI scans who were examined at the Department of
Neuroradiology, University of Wu¨rzburg from 2007 to 2012.
These subjects received MRI scans e.g. to exclude hemorrhage or
thrombosis in acute headache or structural lesions after head
trauma or seizure. This control group consisted of 14 men (median
age 44 years, range 26–72 years) and 22 women (median age 36,
range 16–84 years).
Clinical examination and laboratory tests
As part of the routine work-up all patients underwent
neurological examination and laboratory tests including the
assessment of the glomerular filtration rate (GFR) for renal
function. Normal renal function was defined as GFR $60 ml/
min/1.73 m2, reduced renal function was defined as GFR ,
60 ml/min/1.73 m2 [15–17].
MRI scans
All patients and controls were investigated with a 3 tesla MRI
scanner (Magnetom TIM Trio, Siemens, Germany). The follow-
ing MRI sequences were performed (repetition time, TR; echo
time TE): T1 (TR=295 ms, TE=4.67 ms, slice thickness:
5.0 mm, in plane resolution 0.760.6 mm), PD and T2 (TR:
2150 ms, TE: 11/101 ms, slice thickness: 5.0 mm, in plane
resolution 0.960.9 mm), diffusion-weighted sequence (TR:
3300 ms, TE: 90 ms, slice thickness: 5.0 mm, in plane resolution
1.961.9 mm), time of flight (TOF) 3D MR-angiography (MRA)
(TR: 24 ms, TE: 4.43 ms, slice thickness: 0.6 mm, in plane
resolution 0.560.3 mm), fluid-attenuated inversion recovery
(FLAIR) (TR: 7500 ms, TE: 134 ms, TI (inversion time):
2198 ms, FA (flip angle): 140u, slice thickness: 5.0 mm, in plane
resolution 0.860.8 mm).
To determine WML load we applied the Fazekas score for each
subject on the FLAIR sequences of the individual MRI scans. The
Fazekas score ranges from zero to 3 with zero = no or a single
punctuate white matter lesion, 1= multiple punctuate lesions,
2 = beginning confluence of lesions, 3 = large confluent lesions
[18].
Cerebral arteries were assessed using the 3D-reconstructions of
the TOF-MRA scans. Vessel diameters were measured manually
on identical sagittal planes by the same investigator and using
MagicWeb VA60C_0212 Client Software (Visage Imaging). The
following arteries were studied: common carotid artery (CCA),
middle cerebral artery (MCA), anterior cerebral artery (ACA),
posterior cerebral artery (PCA), and basilar artery (BA). Diameters
were measured as follows: CCA in the middle of the vessel (relative
to the most proximal and distal part of the CCA); MCA at the M1
segment; ACA at the A1 segment; PCA at the P1 segment; BA was
measured in the middle of the vessel (relative to the most proximal
and distal part of the BA). Data of paired arteries were averaged.
All scans were assessed in the same time period and by an
investigator unaware of the diagnoses and of the objectives of the
study.
Statistical analysis
IBM SPSS Statistics 20.0 software (Ehningen, Germany) was
used for statistical analysis. Since data were not normally
distributed the Mann-Whitney-U-test was applied for group
comparisons. Receiver operating characteristic curves (ROC)
were calculated for sensitivity and specificity analyses. P,0.05
was considered significant.
Results
Clinical and laboratory findings
Table 1 and Table S1 give baseline data of Fabry patients,
patients with cerebral ischemic stroke, and of controls. There was
no intergroup difference as for age between Fabry patients and
controls. Patients with cerebral ischemic stroke naturally were
older than patients with FD and controls. In 19 cases patients
carried mutations that are classified as ‘‘classic’’ to date. In further
26 cases patients carried a known mutation. In eight cases intron
polymorphisms were found. In one female patient with typical
clinical presentation and positive family history, reduced alpha-
galactosidase A levels were reported, however, genetic assessment
has not been performed. In seven females multiple polymorphisms
were found but with reduced alpha-galactosidase A activity and
typical clinical presentation and/or positive family history. In the
remaining 26 cases mutations in the alpha-galactosidase gene were
detected that are currently not recognized as ‘‘classic’’, however,
alpha-galactosidase A activity, clinical presentation, and/or family
history were typical for Fabry disease. Regarding central nervous
system signs and symptoms, neurological examination was normal
in 28/30 (93%) men and 54/57 (95%) women with FD. In the
remaining five cases residual signs and symptoms were found after
cerebral infarction such as unilateral facial hypoesthesia (1/87),
unilateral drop in the arm and leg holding tests (2/87), and aphasia
(2/5). Renal function was normal in the majority of men (73%)
and women (88%) with FD.
TIA and strokes are frequent in FD
Table 1 gives data of cerebral events in Fabry patients. Two
men (7%) and three women (5%) had experienced a cerebral
stroke. TIA were reported by two men and women each (7%; 4%).
All TIA and strokes were located in the anterior circulation.
Confluent WML are rare in FD
Table 1 gives data of WML load in Fabry patients. Only one
man (1%) of the entire Fabry population reached a Fazekas score
of 3, and 2 men and women each had a score of 2, while the vast
majority of men and women had no or only few single punctuate
WML. This distribution was not different from that in patients
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with cerebral stroke or in controls. In none of the 87 FD cases a
pulvinar sign was found.
Men with FD have larger arterial diameters of the
posterior circulation than male controls independent of
disease severity
The diameter of the BA and the PCA was larger in FD patients
(BA: median 4.1, range 2.9–6.5 mm; PCA: median 1.9, 1.2–
3.6 mm) compared to controls (BA: median 2.9, range 1.2–
5.5 mm, p,0.001; PCA: median 1.6, range 1.0–2.5 mm, p,
0.01). The difference of BA and PCA diameters between FD and
stroke patients (BA: median 3.2, range 1.3–4.2 mm; PCA: median
1.7, range 1.1–2.4 mm) was not significant. Also, the arterial
diameters in the anterior circulation (CCA, MCA, ACA) did not
differ between groups (data not shown).
Due to the X-chromosomal inheritance of FD the stratification
of the patient groups for gender is crucial. This subgroup analysis
revealed that only male Fabry patients had a larger BA diameter
(p,0.001) and a larger PCA diameter (p,0.05) compared to male
controls (Table 1). No such difference was found when comparing
male FD patients with male stroke patients. The gender-wise
comparison of data for the other study groups (stroke versus
controls) also did not show intergroup differences and again in all
study groups arterial diameters of the anterior circulation were
similar irrespective of gender (Table 1).
We next separated the FD group for renal function as a marker
of disease severity.
Unexpectedly, BA and PCA diameters of male FD patients with
normal and impaired renal function did not differ (Table 2). Both
subgroups had larger BA diameters (GFR $60 ml/min/1.73 m2:
p,0.01; GFR ,60 ml/min/1.73 m2: p,0.01) and PCA diame-
ters (GFR $60 ml/min/1.73 m2: p,0.05; GFR ,60 ml/min/
1.73 m2: p,0.01) when compared with data of male controls
(Table 1, 2; Fig. 1A, B). No such difference was found when
comparing arterial diameters of patients with FD and stroke or of
patients with stroke and controls (Table 1, 2; Fig. 1A, B) although
subgroup analysis revealed a clear trend for the smallest BA
diameters in controls followed by patients with stroke and by
Fabry patients (Fig. 1A). Again, arterial diameters of the anterior
circulation did not differ between subgroups (Table 1, 2; Fig. 1C-
D). The only exception was the finding that female stroke patients
had a smaller ACA diameter than female controls (p,0.001;
Table 1; Fig. 1D). Arterial diameters did not correlate with age, a-
GAL activity, or time since ERT (p.0.05). Also, no difference was
found in vessel diameters of male and female patients with classic
mutations compared to non-classic genetic alterations. None of the
Fabry patients had dolichoectatic arteries.
Table 1. Characteristics of Fabry patients, patients with cerebral ischemic stroke, and of healthy controls.
Fabry patients Stroke patients Controls
M F M F M F
N 30 57 13 7 14 22
Age [years] (median, range) 40 (16–40) 45 (16–73) 58 (49–89) 75 (49–94) 44 (26–72) 36 (16–84)
Time since diagnosis [years]
(median, range)
3 (0–18) 3 (0–35) acute acute n.a. n.a.
Cardiac involvement 21/30 (70%) 24/57 (42%) n.a. n.a. n.a. n.a.
Renal involvement 8/30 (27%) 7/57 (12%) n.a. n.a. n.a. n.a.
Pulmonary involvement 10/30 (33%) 4/57 (7%) n.a. n.a. n.a. n.a.
ERT 23/30 (70%) 13/57 (23%) n.a. n.a. n.a. n.a.
Time since ERT [years]
(median, range)
4.5 (0.1–9.2) 4.9 (1.0–9.2) n.a. n.a. n.a. n.a.
Fazekas 0 15 32 9 1 12 17
Fazekas 1 12 23 2 3 2 4
Fazekas 2 2 2 2 2 0 1
Fazekas 3 1 0 0 1 0 0
TIA/stroke 2/2 2/3 0/13 0/7 0/0 0/0
No TIA/stroke 26 52 0 0 14 22
p-value: arterial diameters
TOF MRA (median; range) M Fabry vs M Fabry vs
M controls M stroke
CCA [mm] 4.2 (3.4–6.5) 4.1 (2.9–5.5) 4.1 (3.2–5.3) 3.7(3.3–4.6) 4.8 (4.0–5.7) 3.9 (2.9–4.7) n.s. n.s.
MCA [mm] 2.4 (1.7–3.1) 2.3 (1.5–3.4) 2.1 (1.6–3.2) 2.2 (1.8–2.7) 2.3 (1.8–3.2) 2.2 (1.3–2.8) n.s. n.s.
ACA [mm] 1.9 (1.3–2.9) 1.7 (1–2.7) 1.5 (1.3–2.3) 1.2 (1.0–1.7) 1.6 (1.1–2.4) 1.7 (1–2.3) n.s. n.s.
PCA [mm] 1.9 (1.4–2.5) 1.9 (1.2–3.6) 1.7 (1.1–2.4) 1.7 (1.1–2.1) 1.5 (1.1–2.5) 1.7 (1–2.2) ,0.05 n.s.
BA [mm] 3.5 (2.7–4.4) 3.1 (2–5) 3.2 (2.6–4.2) 3.2 (1.3–3.6) 2.9 (2.3–5.5) 2.9 (1.2–3.6) ,0.001 n.s.
Abbreviations:
ACA: anterior carotid artery; BA: basilar artery; CCA: common carotid artery; ERT: enzyme replacement therapy; F: female; GFR: glomerular filtration rate; M: male; MCA:
median cerebral artery; n.a.: not applicable; n.s.: not significant; PCA: posterior cerebral artery; TIA: transitory ischemic attack; TOF MRA: time-of-flight magnetic
resonance angiography.
doi:10.1371/journal.pone.0087054.t001
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Large BA diameter distinguishes men with FD from male
controls
ROC analysis revealed that a BA diameter of .3.2 mm has a
high sensitivity (87%) and specificity (86%) for distinguishing men
with FD from male controls (area under the curve [AUC]: 0.859,
p,0.001; Fig. 2A). Statistically, a PCA diameter of .1.7 mm also
distinguished men with FD from male controls, however, with only
a low sensitivity (65%) and specificity (79%; AUC: 0.798, p,0.05;
Fig. 2A). BA and PCA diameters did not distinguish men with FD
from male stroke patients (Fig. 2B). Also, BA and PCA diameters
did not distinguish female FD patients from female stroke patients
or female controls (p.0.05).
Large BA diameter is not associated with increased
incidence of TIA or stroke or high WML load
Nineteen male Fabry patients had a BA diameter of .3.2 mm;
six of these patients also had a PCA of .1.7 mm. 10/19 patients
had a Fazekas score of zero, 7/19 of 1, and 1/19 of 2. Only one
man had a history of stroke in the anterior circulation, while 18/19
of these patients did not have a TIA or stroke medical history.
GFR was normal in 14/19 patients. Of the four men with FD who
reported TIA and stroke in their history only one had a Fazekas
score of 3. BA and PCA diameters in these patients were below the
cut-off values (i.e. were in the range of controls) calculated during
ROC analysis.
Large BA diameter does not change BA blood flow
properties in FD
For seven male FD patients data of BA Doppler sonography
data were available.[11] The median BA diameter of this
subgroup of male patients was larger compared to male controls
(p,0.001), however, BA blood flow parameters (mean, peak, and
end-diastolic blood flow) did not differ from control values (data
not shown).
Discussion
In this large single-center study we show increased BA and PCA
diameters only in men with FD compared to male controls and
independent of disease severity as reflected by renal function.
While we confirm a high number of TIA and strokes in Fabry
patients, our data give no evidence for the predominance of severe
structural cerebral changes in FD reflected by confluent cerebral
WML.
Several case reports of dilated BA have been published [19].
Mitsias and Levine qualitatively reported two cases of FD with
dilated BA; they also reviewed the literature for cerebral
alterations in FD and found indications of dolichoectatic
vertebrobasilar vessels in 51 historical patient reports [20]. In
our cohort of 87 patients we did not find a case of dolichoectatic
vertebrobasilar vessels, however, data cannot be directly compared
due to different methodology. In a previous MRI study, mean BA
and PCA diameters were enlarged in 25 male and female FD
patients compared to healthy controls [12]. Data of the same
patients were later compared with scan records of 26 selected
young patients with cerebral ischemic stroke, and increased z-score
values were reported for the BA diameter of FD patients compared
to stroke patients suggesting a differentiating potential for the BA
diameter [13]. Investigating a FD cohort more than three times
bigger, we found larger BA and PCA diameters only in men with
FD compared to male controls. In our cohort, BA diameter did
not distinguish FD patients from patients with cerebral stroke.
Why male Fabry patients have a larger BA and PCA diameter
than male controls and if a difference of 0.6 mm for the BA
diameter, as was found here, is of biological relevance remains
Table 2. Characteristics of male and female Fabry patients with impaired renal function (advanced disease severity) and normal
renal function (low disease severity).
M GFR,60 M GFR$60 F GFR,60 F GFR$60
N 8 22 7 50
Age [years] (median, range) 46 (39–56) 34 (16–65) 57 (44–69) 42 (16–73)
Time since diagnosis [years] (median, range) 9 (0–18) 3 (0–16) 3 (0–10) 3 (0–35)
ERT 6 18 3 7
No ERT 2 4 4 43
Fazekas 0 4 11 4 28
Fazekas 1 4 8 3 19
Fazekas 2 0 2 0 2
Fazekas 3 0 1 0 0
TIA/stroke 0/2 2/0 1/0 1/3
No TIA/stroke 6 20 6 46
TOF MRA (median; range):
CCA [mm] 4.2 (3.–5.2) 4.2 (3.4–6.5) 3.7 (3.5–4.3) 4.1 (2.9–5.5)
MCA [mm] 2.4 (1.7–2.5) 2.4 (1.7–3.1) 2.2 (1.5–2.9) 2.3 (1.7–3.4)
ACA [mm] 2 (1.4–2.2) 1.9 (1.3–2.9) 1.4 (1.2–1.8) 1.8 (1–2.7)
PCA [mm] 2.2 (1.8–2.4) 1.9 (1.4–2.5) 1.8 (1.3–3.6) 1.9 (1.2–2.7)
BA [mm] 3.6 (3.3–4.2) 3.5 (2.7–4.4) 3 (2.8–3.2) 3.1 (2–5)
Abbreviations:
ACA: anterior carotid artery; BA: basilar artery; CCA: common carotid artery; ERT: enzyme replacement therapy; F: female; GFR: glomerular filtration rate; M: male; MCA:
median cerebral artery; TOF MRA: time-of-flight magnetic resonance angiography; PCA: posterior cerebral artery; TIA: transitory ischemic attack.
doi:10.1371/journal.pone.0087054.t002
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uncertain. It is of note that none of our FD patients had a cerebral
ischemic stroke in the posterior circulation. Only one patient in the
cohort of men with FD and enlarged BA diameter had a stroke in
his medical history; the Fazekas score was zero or 1 in the vast
majority of cases. Also, when regarding our previously published
Doppler sonography data of those patients that had enlarged
vessel diameters in the current study, we did not find a change in
cerebral blood flow velocities [11]. Moore et al., using positron
emission tomography (PET) and magnetic resonance arterial spin
tagging (AST-MR), described cerebral hyperperfusion in male
Fabry patients [21,22]. However, how and if enlargements of
proximal cerebral artery diameters and changes in regional
cerebral blood flow measured by AST-MR are connected remains
to be studied.
In our subgroup of 30 FD men, a BA diameter of.3.2 mm had
a high sensitivity and specificity for distinguishing them from male
controls. The results of the ROC analysis need to be interpreted
with caution. To judge the clinical relevance of this potential
diagnostic tool, a larger number of patients and a comparison with
an already validated diagnostic tool would be desirable. We did
not find a difference in BA diameter between our male FD patients
and male stroke controls. One limitation of our study is that the
group of patients with ischemic stroke was older than the group of
Fabry patients. This is due to the fact that ischemic stroke is a
disease of advanced age. However, since cerebral arterial
diameters of stroke patients did not differ substantially from
controls and since cerebral vessel diameters did not correlate with
age we believe that our results were not influenced.
The pathogenesis of enlarged cerebral vessels is as yet
incompletely understood. Factors that have been discussed are
reduced sympathetic innervation of proximal cerebral arteries
[6,9], enhanced release of nitric oxide [23], and glycosphingolipid
deposition in vascular smooth muscle cells [20]. The latter is
supported by the few available autopsy reports [24,25] and by the
fact that enlarged BA have also been described in other lysosomal
storage disorders like late onset Pompe disease [26]. In this context
treatment with ERT might be effective in reducing glycosphingo-
lipid deposition in the smooth muscle cells of vessel walls, however,
no data are available to support this assumption so far. Another
factor that potentially might influence vessel diameters in patients
with FD is the level of blood carbon dioxide due to pulmonary
involvement [27]; this parameter was not assess in our study,
however, there were no clinical signs for severe pulmonary
involvement in any of our patients.
There is no explanation, at present, why the posterior
circulation is exclusively affected. In this context our finding that
disease severity does not influence cerebral artery diameters is
surprising. The X-chromosomal inheritance leads to a worse
clinical manifestation in men and it is the men who have larger
arterial diameters in the posterior circulation. However, although
the peripheral nervous system deteriorates with advanced disease
severity in FD [14] the brain seems to be protected. This is striking
Figure 1. Cerebral artery diameters. Boxplots show the cerebral artery diameters of patients with Fabry disease (FD), cerebral ischemic stroke
(St), and controls (Co) stratified for gender and renal function (A-D). (A) Male Fabry patients had a larger BA diameter independent of renal function.
(B) Male Fabry patients had a larger PCA independent of renal function. (C) Subject groups did not differ in MCA diameters. (D) Female stroke patients
had a smaller ACA diameter compared to female controls. The three study groups were compared gender-wise with each other. *p,0.05; **p,0.01.
Patient numbers: Fabry male, GFR,60: n = 8; Fabry male, GFR$60: n = 22; Fabry female, GFR,60: n = 7; Fabry female, GFR$60: n = 50; Stroke male:
n = 13; Stroke female: n = 7; Controls male: n = 14; Controls female: n = 22.
doi:10.1371/journal.pone.0087054.g001
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and further studies are needed to understand the underlying
mechanisms.
In a previous study a high WML load on FLAIR images was
reported in patients with FD [5]. Applying a similar semiquan-
titative scale, we could not confirm these data, and the lesion load
was low in most of our patients, also in those with severe renal and
cardiac involvement. In another study the quantitative assessment
of WML on T2-weighted MRI scans in a cohort of 50 Fabry
patients including children revealed that WML occurred in more
than 70% of cases in the periventricular white matter region and
that WML increased with age [28]. The individual WML was not
reported and genders were not differentiated. The Fabry Outcome
Survey (FOS) database reports WML in 38/84 patients, however
without specification of methods and of disease severity [29],
therefore a direct comparison with our data is not possible.
However, it is conceivable that treatment has improved over time
and that the burden of WML is therefore lower in more recent
studies than in previous cohorts. It is also important to note that
fewer patients with advanced FD can be investigated with MRI
today due to the higher number of patients carrying defibrillators
or pacemakers because of cardiac involvement [30]. This might
induce a bias when cross-comparing data of earlier and current
studies that might differ in the number of severely affected patients
suitable for MRI. Another aspect that needs to be considered is the
genotype of the patient population. Information on the exact and
individual genetic alterations of the enrolled patients and if these
mutations are recognized as classic or not to data is not provided
in the majority of Fabry studies. Here we did not find differences
in arterial diameters when comparing the different subtypes of
genetic alterations in our cohort, however, one caveat is that these
subgroups were small.
The pathophysiology of WML in FD is still elusive. The few
available reports show lacunar infarctions and narrowing of small
arterioles [24,31] which might underlie WML, however, system-
atic data from larger studies are missing. So far no Fabry-specific
pattern of WML spread has been found. The reports range from a
focus in midbrain and brainstem [32] to predominantly in the
carotid region [33]. The sensitivity and specificity of the pulvinar
sign – as a potential indirect hint for disturbance of the posterior
circulation – for Fabry disease is low. In two studies the presence of
the pulvinar sign was investigated in men with Fabry disease
comparing MRI scans with those of healthy controls [34,35]. In
both studies the sensitivity was ,10%. Among studies investigat-
ing Fabry patients only with regard to a positive pulvinar sign data
are conflicting (e.g. [6,36]). Also, the biological meaning of WML
is not well understood. Longitudinal studies investigating WML as
potential risk factors for cerebral infarctions in FD have not been
performed yet. Such studies would be needed to decide if high
WML load requires special prophylactic precautions like anti-
platelet drugs.
Supporting Information
Table S1 Characteristics of study population including
treatment regimen with enzyme replacement therapy. 1
Alpha-galactosidase alpha 0,2 mg/kg every second week 2 Alpha-
galactosidase beta 1 mg/kg every second week 3 Alpha-galacto-
sidase beta 1 mg/kg every second week, but with reduced dose
during the period of product shortage 4 Alpha-galactosidase beta
1 mg/kg every second week, switched to alpha-galactosidase alpha
during the period of product shortage Abbreviations: ERT:
enzyme replacement therapy; F: female; M: male; cMRI: cranial
magnetic resonance imaging.
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Figure 2. Sensitivity and specificity analysis of the basilar and
posterior cerebral arteries. Graphs show receiver operating curves
(ROC) for the sensitivity and specificity of BA and PCA diameters in male
Fabry patients compared to male controls (A) and compared to male
patients with cerebral ischemic stroke (B). With a cut-off value of
3.2 mm the BA diameter distinguished male Fabry patients from male
controls with a sensitivity of 87% and specificity of 86% (A). The PCA
diameter distinguished male Fabry patients from male controls at a cut-
off value of 1.7 mm and with a sensitivity of 65% and a specificity of
79% (A). BA and the PCA diameters did not distinguish male Fabry
patients from male stroke patients (B).
doi:10.1371/journal.pone.0087054.g002
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